Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216523 | 1.00 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1ATAD2 | |
| SCHEMBL8218887 | 0.78 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1UCHL1 | |
| SCHEMBL8222142 | 0.73 | ADAM17 (0.50) | ADAM17TMIGD3ADORA1UCHL1USP30 | |
| SCHEMBL13542671 | 0.72 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1ATAD2 | |
| SCHEMBL8217845 | 0.72 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1ATAD2 | |
| SCHEMBL12216519 | 0.72 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1ATAD2 | |
| SCHEMBL8214865 | 0.72 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1ATAD2 | |
| SCHEMBL16356417 | 0.72 | ADAM17 (0.46) | ADAM17TMIGD3ADORA1NTMT1ATAD2 | |
| SCHEMBL3682586 | 0.71 | GPR119 (0.38) | LMNANPSR1MEN1KMT2AGPR119 | |
| SCHEMBL31598413 | 0.71 | TRPV3 (0.36) | USP30L3MBTL1LMNANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | ADAM17 4/4885TMIGD3 1814/4885ADORA1 2962/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ADAM17 11/4885TMIGD3 2727/4885ADORA1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.